LCA-0321 is a LYTAC degrader designed to specifically bind and rapidly deplete anti-TSHR autoantibodies, the underlying cause of Graves’ disease and its extrathyroidal manifestations, including ...

AbbVie projects they'll generate sales of over $31 billion ... postmenopausal osteoporosis treatment Evenity; and Tepezza, ...

AbbVie's combination antibiotic Emblaveo has gotten federal approval to treat complicated intra-abdominal infections, making it the first and only such therapy approved to fight antimicrobial ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other stocks. Jim Cramer, the host of Mad Money, on Tuesday, took a close look at President Donald ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting off on a very different note. According to iSpot.TV’s analysis of ...

Shares of AbbVie (NYSE: ABBV) were jumping 7.1% higher as of 11:10 a.m. ET on Friday after rising as much as 9.2% earlier in the day. The nice gain stemmed from the big drugmaker's 2024 fourth ...

CEO Rob Michael highlighted AbbVie's strong Q4 2024 performance, which exceeded initial guidance with $56.3 billion in total net revenues for the year, up 4.6% operationally, despite $5 billion in ...

AbbVie (ABBV) came out with quarterly earnings of $2.16 per share, beating the Zacks Consensus Estimate of $2.13 per share. This compares to earnings of $2.79 per share a year ago. These figures ...

AbbVie reported its 2024 Q4 results on Friday. Investors especially liked the drugmaker's 2025 outlook. AbbVie reported Q4 net revenue of $15.1 billion, up 5.6% and higher than the average ...

a Represents net earnings attributable to AbbVie Inc. Intangible asset impairment primarily reflects partial impairment charges related to the U.S. Imbruvica and CoolSculpting intangible assets.